Luglio 2022: Secondo l’ultima ricerca condotta da Emergen Research, il mercato globale della terapia con cellule CAR T ha raggiunto una dimensione di 1.29 miliardi di dollari nel 2021 e si prevede che registrerà un CAGR dei ricavi del 24.9% nel corso del periodo di previsione. Si prevede che la crescente incidenza del cancro in tutto il mondo e il crescente tasso di mortalità causato dal cancro saranno i principali motori della crescita dei ricavi nel mercato globale della terapia cellulare CAR-T nel corso del periodo di previsione. L’espansione delle attività di sperimentazione clinica a un ritmo vertiginoso, la proliferazione di fusioni e acquisizioni e il fascino delle offerte pubbliche iniziali sono tutti fattori che contribuiscono alla crescita dei ricavi nel mercato globale della terapia con cellule CAR T.
The primary objective of the report is to provide an overview of the market, including product scope, growth prospects, and potential risks. In-depth information about each participant in the global Terapia con cellule T AUTO market, including that participant’s global standing, financial status, product launch, and business expansion plans, is included in the report. The participants in the market are concentrating their efforts on the creation of a variety of strategies, including partnerships, mergers and acquisitions, joint ventures, product launches, and investments in research and development.
According to the findings of the study, there are certain types of dangers and difficulties that can serve as an obstacle for a company. Granularity can be added to the overall research by performing an in-depth analysis of the Terapia con cellule T AUTO market in the context of various aspects of the larger environment, such as the social, political, economic, and technological settings. In addition, the study generates real-time data on essential aspects such as sales, profits, gross margin, and growth prospects to demonstrate how going forward the company will see a significant upswing in its performance.
Ulteriori risultati significativi del rapporto lo indicano
In 2021, the segment of diffuse large B-cell linfoma was responsible for the majority of the rapid revenue share. A cancer of the lymphatic system, which is an essential component of the immune system, called diffuse large B-cell lymphoma has a rapid growth rate. It has an effect on the blood cells that generate antibodies, which are used to fight infections. In certain instances, DLBCL can be cured. The majority of patients suffering from DLBCL have a favourable response to initial treatments such as chemotherapy. In the case of some people, the illness either becomes resistant to treatment, which means that it no longer responds to it, or it relapses, which means that it returns after treatment has been completed. These patients may be candidates for treatment with Terapia con cellule T del recettore dell'antigene chimerico, which utilises the patient’s own immune cells in the fight against DLBCL. T-cells are taken out of the patient’s blood, modified in the laboratory with so-called chimeric antigen receptors that help in recognising and destroying cancer cells, and then reintroduced into the patient’s blood again. This process is repeated several times.
In 2021, the hospital segment was responsible for a fair amount of the total revenue. The CAR T-cell therapy will reprogramme the patient’s T-cells so that they will target the antigens produced by the tumour. CAR T-cell therapy has shown full remission rates of 80 to 90 percent in younger patients with B-cell acute lymphoblastic leukaemia, and it has shown a full remission rate of 40 percent in patients with symptomatic B-cell linfomi non Hodgkin who have failed several prior lines of therapy. Both of these patient populations have B-cell acute lymphoblastic leukaemia.
Le società chiave che attualmente operano sul mercato sono analizzate ulteriormente in questo rapporto, così come i loro profili aziendali, portafogli di prodotti, strategie di espansione e alleanze strategiche. Alcuni esempi di questi tipi di alleanze includono fusioni e acquisizioni, collaborazioni e joint venture. Oltre a ciò, fornisce punti salienti sui risultati e sulla situazione finanziaria dell'azienda, nonché approfondimenti sulla portata del mercato e sulla posizione globale dell'azienda.
Aziende profilate nel mercato globale della terapia cellulare T CAR:
Novartis AG, Pfizer Inc., CARsgen Therapeutics Co., Ltd, Daiichi Sankyo Company, Limited, Bristol-Myers Squibb Company, Astellas Pharma Inc., BioNTech SE, Biocad, F. Hoffmann-La Roche Ltd. ed Eli Lilly and Company .
Maggiori informazioni sul rapporto sul mercato globale Terapia a cellule T per auto su: https://www.emergenresearch.com/industry-report/car-t-cell-therapy-market
